Colleagues for Excellence

Bisphosphonate-Associated Osteonecrosis of the Jaw

Published for the Dental Professional Community by the American Association of Endodontists

www.aae.org/colleagues
There has been a burgeoning demand for information about bisphosphonates over the past 10 years due to an increasing awareness of this drug’s rare adverse side effect of osteonecrosis of the jaw. The medical and dental communities’ realization of this complication has been correspondingly disseminated to the public through various media outlets, websites and position statements proffered by the United States Food and Drug Administration, as well as several pharmaceutical companies. One only has to venture through the multitude of Internet search engines to see that the legal community is also an interested party to bisphosphonate-associated osteonecrosis of the jaw.

The dental profession is in an advantageous position to educate the public and fellow health care professionals, as well as be at the forefront in diagnosing this condition. It is incumbent upon dental health care providers to be knowledgeable about this issue and acquainted with the most current treatment recommendations and guidelines available. The goal of this informational article is to enhance your understanding about this frequently prescribed class of drugs with regards to its pharmacokinetics, mode of action, types of bisphosphonates and the implications of BONJ.

The first case reports describing a possible relationship between bisphosphonate therapy and osteonecrosis of the jaw published in the Journal of Endodontics and the Journal of the American Dental Association termed the phenomenon as bisphosphonate-associated osteonecrosis of the jaw or BONJ. Other dental specialty communities and authors have referred to the condition by various other names including bisphosphonate-related osteonecrosis of the jaw and bisphosphonate-induced osteonecrosis of the jaw. With the advent of antiresorptive agents other than bisphosphonates being associated with ONJ, the nomenclature of the condition has continued to evolve. In recognition of these other antiresorptive agents, the ADA Council on Scientific Affairs, in its November 2011 Recommendations for Managing the Care of Patients Receiving Antiresorptive Therapy for Prevention and Treatment of Osteoporosis, proposed that all cases of ONJ related to the administration of antiresorptive therapeutic agents be termed antiresorptive agent-induced osteonecrosis of the jaw. To avoid confusion and for purposes of continuity, the AAE Specialty Committee on Bisphosphonates recommends the continued use of the term bisphosphonate-associated osteonecrosis of the jaw with the understanding the that term is meant to be inclusive of these other antiresorptive agents.

Use of Bisphosphonates

In 2006, total U.S. prescriptions for oral bisphosphonates exceeded 30 million.1 America’s aging baby boomer population will likely produce an amplification of those numbers over the next two decades. Bone fractures are the biggest problem facing most older individuals with bone disease, especially those with osteoporosis. The cumulative impact of these fractures can be devastating. Osteoporotic fractures in the United States in 1995 led to more than half a million hospitalizations, over 800,000 emergency room encounters, more than 2.6 million physician office visits and the placement of nearly 180,000 individuals into nursing homes (U.S. Surgeon General Report 2004). It has been estimated that, over a 10-year period, white women age 45 and older in the United States could experience 5.2 million fractures of the hip, spine or forearm, resulting in two million person-years of disability related to the fractures. Bisphosphonates are generally prescribed in the prevention and treatment of resorptive bone diseases such as osteoporosis and bone metastasis (with or without hypercalcemia) associated with breast and prostate cancers. They are also recognized as an effective therapeutic for Paget’s disease (osteodystrophy deformans) and other conditions that precipitate bone fragility, such as chronic renal disease in patients undergoing dialysis.2

Bisphosphonates and Osteonecrosis of the Jaw

Bonefos® (clodronate) and Didronel® (etidronate), both first-generation bisphosphonates do not have an amino group moiety (nitrogen-containing) on the R2 long side-chain. It is the R2 side-chain that imparts the potency and method of affect on bone cells. Therefore, first-generation bisphosphonates (non-nitrogen containing) do not appear to be implicated in BONJ. Second- and third-generation bisphosphonates (nitrogen-containing), including Zometa® (zoledronate), Reclast® (zoledronate), Aredia® (pamidronate), Boniva® (ibandronate), Actonel® (risedronate) and Fosamax® (alendronate), inhibit specific enzymatic activity necessary for osteoclast bone resorption.3-7 Bisphosphonates are administered either parenterally (intravenously) or orally. What is significant to these two routes of administration is the bioavailability of the drug. The oral bioavailability is in the area of one percent due to the higher ionization at physiologic pH when absorbed through the intestinal mucosa.8 Greater bioavailability through parenteral administration and concomitant potency are likely responsible for the higher incidence of BONJ in this group.

The accumulated body of literature is replete with case reports, letters to the editor, reviews and drug alerts by the
U.S. FDA and pharmaceutical companies. This collective information points to an association between bisphosphonates and ONJ. With limited current available randomized controlled trials or higher levels of clinical evidence, the following information is presented based mostly on retrospective analysis of case reports and expert opinions.

Other Antiresorptive Agents and Osteonecrosis of the Jaw

Nonbisphosphonate antiresorptive agents have recently become available. One such agent is Prolia® (denosumab), which received FDA approval in 1997 for the treatment of osteoporosis in postmenopausal women. Denosumab is a monoclonal antibody that acts in a similar fashion to bisphosphonates, reducing bone resorption by inhibiting osteoclast function. There is at least one case report of ONJ developing in a cancer patient taking denosumab. Other antiresorptive agents that could prove to be associated with ONJ include cathepsin K-inhibitors, anabolic agents and angiogenesis inhibitors. One such cathepsin K-inhibitor is odanacatib, which increased bone mineral density in postmenopausal women after two years with side effects similar to a placebo.

Signs and Symptoms of BONJ

- An irregular mucosal ulceration with exposed bone in the mandible or maxilla persisting for longer than eight weeks
- Pain or swelling in the affected jaw without evidence of dental pathology
- Infection with or without purulence
- An altered sensation (e.g., numbness or heavy sensation)

Additional important issues related to BONJ include:

- The site of occurrence of osteonecrosis is the jaws; presentation occurs more frequently in the mandible than the maxilla.
- The exact mechanism for bisphosphonate–associated ONJ is unknown. However, evidence suggests bisphosphonates inhibit osteoclastic function, induce apoptosis of osteoclasts and inhibit osteoclast differentiation from precursors. They may also inhibit angiogenesis but this effect is less clear and may be variable.
- Screening tests used for the purpose of determining a patient’s risk of developing BONJ, such as C-terminal cross-linking telopeptide of Type I collagen (CTX) and urinary N-telopeptide of Type I collagen (NTX) levels, do not display sufficient evidence to recommend their use.
- The treatment for BONJ is problematic. Case reports document no response or a limited response to local surgical wound debridement, marginal or segmental resection, antibiotics and hyperbaric oxygen. Therefore, recognition of risk factors and application of preventive dental treatment procedures are important for patients taking I.V. and perhaps oral bisphosphonates.

Common risk factors associated with BONJ:

- History of taking bisphosphonates, especially I.V. formulations.
- At this time, the concurrent use of steroids has not consistently been found to be a risk factor. Literature to the contrary is largely based on expert opinion and hypothesis. Literature to the contrary is largely based on expert opinion and hypothesis. Literature to the contrary is largely based on expert opinion and hypothesis. Literature to the contrary is largely based on expert opinion and hypothesis. Literature to the contrary is largely based on expert opinion and hypothesis. Literature to the contrary is largely based on expert opinion and hypothesis.
- Previous history of cancer (e.g., multiple myeloma or metastatic disease to bone), osteoporosis, Paget’s disease, chronic renal disease on dialysis or other indications for bisphosphonate treatment.
- A history of a traumatic dental procedure. Most case reports occur after a tooth extraction, although other traumatic dental procedures may also be associated with the occurrence of ONJ. One case report describes BONJ occurring six months after placement of five dental implants with the subsequent loss of all implants. Several reports indicate the spontaneous development of BONJ without a prior traumatic dental procedure.

It is now well-established that BONJ is a class effect of the subclass termed nitrogen-containing bisphosphonates (i.e., may occur with all nitrogen-containing bisphosphonates with the incidence varying according to potency or other factors) rather than a drug effect (i.e., observed with only a few nitrogen-containing bisphosphonates). To date, the majority of reports have described ONJ occurring in patients undergoing bisphosphonate infusion (e.g., Zometa®, Reclast®).
[zoledronate] and Aredia® (pamidronate). Nevertheless, in several publications, oral bisphosphonates have been associated with ONJ. A FDA Office of Drug Safety Post-Marketing Safety Review stated that BONJ “may be a class effect.” Revised product packages for oral bisphosphonate medications (e.g., Fosamax® [alendronate] and Actonel® [risedronate] list BONJ as a possible adverse side effect.

**Incidence of BONJ**

Currently, there are few studies that adequately address the incidence of BONJ. However, recent literature suggests that patients receiving bisphosphonates intravenously for cancer therapy for extended periods (e.g., >2 years with zoledronate) have a risk of developing BONJ of between 0.8% and 20%, and patients receiving oral bisphosphonate therapy have a risk of developing BONJ of between 0 and 0.04%. In one survey of respondents taking oral bisphosphonates, the risk of developing BONJ was approximately 0.1%. However, safety data acquired recently from two controlled studies in patients receiving an oral bisphosphonate, Fosamax® (alendronate), showed no correlation between oral bisphosphonates and BONJ. Study 1 tested the effect of alendronate on alveolar bone in 335 patients in a randomized clinical trial using a placebo or 70 mg of alendronate weekly for two years. Study 2, a longitudinal, single-blind, controlled design compared success in 50 consecutive patients. The study covered implant success and safety, also determining occurrence of BONJ. No incidence of BONJ was observed in either study. The conclusion of these two studies was that oral bisphosphonate usage was not associated with occurrence. However, the maximum length of follow-up in these studies was only three years and the sample sizes may not have been large enough to identify the small incidence of BONJ. To date, there are no case reports that directly or indirectly implicate endodontic treatment in the development of BONJ. One case report suggested an association, but the assertion was not supported by the evidence presented in the report.

Pending the availability of more definitive information, prudence should govern all patient treatment considerations for individuals on bisphosphonates. The magnitude of risk for BONJ likely varies with the bisphosphonate taken, duration of usage, patient factors (e.g., concurrent drugs, diseases, etc.) and dental treatment. The existing knowledge at this time strongly suggests that patients on I.V. bisphosphonates have a higher risk for developing BONJ, while patients taking oral bisphosphonates have a significantly lower risk. However, even if there were numerous published studies that adequately addressed the incidence of BONJ, it would still be impossible to predict a specific patient’s risk.

**Commonly Prescribed Bisphosphonates**

<table>
<thead>
<tr>
<th>Subclass of Bisphosphonate</th>
<th>Generic Name</th>
<th>Trade Name</th>
<th>Route of Administration</th>
<th>Potency Ratings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aminobisphosphonate</td>
<td>Zolendronate</td>
<td>Zometa®, Reclast®</td>
<td>I.V.</td>
<td>10,000</td>
</tr>
<tr>
<td>Aminobisphosphonate</td>
<td>Pamidronate</td>
<td>Aredia®</td>
<td>Oral &amp; I.V.</td>
<td>100</td>
</tr>
<tr>
<td>Aminobisphosphonate</td>
<td>Alendronate</td>
<td>Fosamax®</td>
<td>Oral</td>
<td>500</td>
</tr>
<tr>
<td>Aminobisphosphonate</td>
<td>Ibandronate</td>
<td>Boniva®</td>
<td>Oral &amp; I.V.</td>
<td>1,000</td>
</tr>
<tr>
<td>Aminobisphosphonate</td>
<td>Risedronate</td>
<td>Actonel®</td>
<td>Oral</td>
<td>2,000</td>
</tr>
<tr>
<td>Nonaminobisphosphonate</td>
<td>Tiludronate</td>
<td>Skelid®</td>
<td>Oral</td>
<td>10</td>
</tr>
<tr>
<td>Nonaminobisphosphonate</td>
<td>Clodronate</td>
<td>Bonefos®, Loron®, Ostac®</td>
<td>Oral</td>
<td>10</td>
</tr>
<tr>
<td>Nonaminobisphosphonate</td>
<td>Etidronate</td>
<td>Didronel®</td>
<td>Oral</td>
<td>(potency relative to that of etidronate)</td>
</tr>
</tbody>
</table>

**Recommendations and Guidelines**

The following is recommended when considering the endodontic implications in treating patients taking bisphosphonates:

**I.V. Bisphosphonate Guidelines:**

- Patients taking I.V. bisphosphonates are at higher risk for developing BONJ. Preventive procedures are very important to reduce the risk of developing BONJ because treatment of BONJ is not predictable at this time. Preventive care might include caries.
control, conservative periodontal and restorative treatments, and, if necessary, appropriate endodontic treatment. Similar to the management of the patient with osteoradionecrosis, this might include nonsurgical endodontic treatment of teeth that otherwise would be extracted. Nonrestorable teeth may be treated by removal of the crown, endodontic treatment of remaining roots and restoration similar to preparing an overdenture abutment.

- Surgical procedures such as tooth extractions, endodontic surgical procedures or placement of dental implants appear to pose an increased risk for developing osteonecrosis of the jaws and should be avoided if possible.

**Oral Bisphosphonate Guidelines:**

- Patients taking oral bisphosphonates are at lower risk for developing BONJ. Appropriate clinical procedures might include intraoral examination, indicated dental procedures (e.g., regular checkups, caries control, indicated periodontal and restorative treatments), and patient education about the symptoms of bisphosphonate-associated osteonecrosis of the jaws and their relatively low risk of developing ONJ from surgery or soft tissue procedures.

**General Guidelines and Recommendations:**

- Recognize the risk factors of BONJ.
- As usual, informed consent for endodontic procedures should involve a discussion of risks, benefits and alternative treatments with the patient.
- Consider BONJ when developing a differential diagnosis of nonodontogenic pain.
- Utilize the entire health care team, including the patient’s general dentist, oncologist and oral surgeon, when developing treatment plans for these patients.
- Cases of BONJ should be reported to the U.S. FDA MedWatch Online at [www.accessdata.fda.gov/scripts/medwatch](http://www.accessdata.fda.gov/scripts/medwatch).
- Additional background information on how to report adverse effects of drugs can be found at [www.fda.gov/opacom/backgrounders/problem.html](http://www.fda.gov/opacom/backgrounders/problem.html).
- Be aware that the knowledgebase for BONJ is rapidly increasing and it is likely that these recommendations may change over time. The prudent practitioner is encouraged to continually review publications for new developments and treatments in antiresorptive therapy.

---

**Figure 1.** (A) Clinical presentation of posterior left quadrant and exposed bone #15. (B) Periapical radiograph of tooth #15 at presentation. (C) Panoramic radiograph at presentation. Sarathy et al. Bisphosphonate-Associated Osteonecrosis of the Jaws and Endodontic Treatment: Two Case Reports. Journal of Endodontics 2005;10:759-63. ©Copyright 2005. Reproduced with permission.

**Figure 2.** (A) View of upper left quadrant after sectioning of pontic. (B) Close-up view of tooth #15 and bone exposure. (C) Intraoperative view demonstrating intact sinus membrane. (D) Immediate postoperative close-up of panoramic film of operative site showing intact sinus wall. Sarathy et al. Bisphosphonate-Associated Osteonecrosis of the Jaws and Endodontic Treatment: Two Case Reports. Journal of Endodontics 2005;10:759-63. ©Copyright 2005. Reproduced with permission.


References


The AAE wishes to thank Dr. Gary G. Goodell for authoring this issue of the newsletter, as well as Dr. Marc Balson for authoring the AAE’s Winter 2007 newsletter on this topic. Thanks also to the following article reviewers: Drs. Sidney L. Bourgeois of the American Association of Oral and Maxillofacial Surgeons, James J. Jespersen, James C. Kulild, Robert S. Roda, James F. Wolcott and Susan L. Wolcott.

---

**Exclusive Bonus Materials**

This issue of the *ENDODONTICS: Colleagues for Excellence* newsletter is available online at www.aae.org/colleagues with the following exclusive bonus materials:

- AAE position statement, Endodontic Implications of Bisphosphonate-Associated Osteonecrosis of the Jaw.
- “Ask the Author” Discussion Board for all of your questions and comments

**All back issues** of this newsletter are also available for your ongoing reference online.

**Earn CE With Colleagues**

With an annual subscription to the AAE Live Learning Center you can earn CE credit for the *ENDODONTICS: Colleagues for Excellence* newsletter series. Visit www.aae.org/livelearningcenter for more information.

---

The information in this newsletter is designed to aid dentists. Practitioners must use their best professional judgment, taking into account the needs of each individual patient when making diagnosis/treatment plans. The AAE neither expressly nor implicitly warrants against any negative results associated with the application of this information. If you would like more information, consult your endodontic colleague or contact the AAE.

American Association of Endodontists
211 E. Chicago Ave., Suite 1100
Chicago, IL 60611-2691
info@aae.org • www.aae.org

www.facebook.com/endodontists
www.youtube.com/rootcanalspecialists
@AAENews, @SavingYourTeeth